Share chart PFIZER
About
Pfizer Inc. обнаруживает, разрабатывает, производит, продает, распространяет и продает биофармацевтические продукты по всему миру. Он предлагает лекарства и вакцины в различных терапевтических областях, включая сердечно-сосудистый метаболизм и обезболивание, под торговыми марками Eliquis, Chantix / Champix и Premarin; биопрепараты, малые молекулы, иммунотерапевтические препараты и биоаналоги под брендами Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena и Braftovi; стерильные инъекционные и противоинфекционные препараты торговых марок Сульперазон, Медрол, Зитромакс, Вифенд и Панзига.
More detailsЦена ао | 28.32 |
---|---|
P/E | 12.86 |
P/S | 4.04 |
P/BV | 3.3 |
EV/EBITDA | 13.17 |
Дивиденд ао | 1.64 |
Див.доход ао | 4.49 |
EBITDA | 19.75 |
Сайт | http://www.pfizer.com |
Число акций ао | 5.709 млрд |
Выручка | 51.75 |
ISIN | US7170811035 |
Валюта | usd |
IPO date | 2012-08-13 |
Sector | Health Care |
Industry | Pharmaceuticals |
Валюта отчета | usd |
Change price per day: | -1.1859% (28.67) |
---|---|
Change price per week: | -2.07% (28.93) |
Change price per month: | -2.34% (29.01) |
Change price per 3 month: | +2.27% (27.7) |
Change price per half year: | +6.3% (26.65) |
Change price per year: | -14.9% (33.29) |
Change price per 3 year: | -51.75% (58.71) |
Change price per 5 year: | -22.79% (36.69) |
Change price per 10 year: | -10.24% (31.5612) |
Change price per year to date: | -1.5978% (28.79) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
1.44% | 0.42 | II кв. 2024 | 24.07.2024 | 26.07.2024 | 12.08.2024 |
1.51% | 0.42 | I кв. 2024 | 07.05.2024 | 09.05.2024 | 24.05.2024 |
1.65% | 0.42 | IV кв. 2023 | 23.01.2024 | 25.01.2024 | 09.02.2024 |
1.36% | 0.41 | III кв. 2023 | 07.11.2023 | 09.11.2023 | 24.11.2023 |
1.13% | 0.41 | II кв. 2023 | 25.07.2023 | 27.07.2023 | 11.08.2023 |
0.86% | 0.41 | IV кв. 2022 | 24.01.2023 | 26.01.2023 | 10.02.2023 |
0.87% | 0.4 | III кв. 2022 | 01.11.2022 | 03.11.2022 | 18.11.2022 |
0.77% | 0.4 | II кв. 2022 | 26.07.2022 | 28.07.2022 | 12.08.2022 |
0.8% | 0.4 | IV кв. 2021 | 25.01.2022 | 27.01.2022 | 11.02.2022 |
0.7% | 0.39 | III кв. 2021 | 02.11.2021 | 04.11.2021 | 19.11.2021 |
0.88% | 0.39 | II кв. 2021 | 27.07.2021 | 29.07.2021 | 13.08.2021 |
0.94% | 0.38 | I кв. 2021 | 04.05.2021 | 06.05.2021 | 21.05.2021 |
1.03% | 0.38 | IV кв. 2020 | 26.01.2021 | 28.01.2021 | 12.02.2021 |
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
25.02.2023 | 28.02.2023 | Hwang Angela President, Global Biopharma |
Purchase | 22.89 | 464 049 | 20273 | 0 | 0 | link |
25.02.2023 | 28.02.2023 | DAMICO JENNIFER B. SVP & Controller |
Purchase | 22.89 | 255 224 | 11150 | 0 | 0 | link |
25.02.2023 | 28.02.2023 | McDermott Michael Executive Vice President |
Purchase | 22.89 | 324 534 | 14178 | 0 | 0 | link |
22.02.2023 | 24.02.2023 | DAMICO JENNIFER B. SVP & Controller |
Purchase | 30.17 | 315 458 | 10456 | 0 | 0 | link |
22.02.2023 | 24.02.2023 | JOHNSON RADY A Executive Vice President |
Purchase | 30.17 | 952 105 | 31558 | 0 | 0 | link |
16.12.2022 | 16.12.2022 | BOURLA ALBERT Chairman & CEO |
Purchase | 27.25 | 6 058 440 | 222328 | 0 | 0 | link |
14.12.2022 | 16.12.2022 | LANKLER DOUGLAS M Executive Vice President |
Purchase | 26.29 | 2 672 590 | 101658 | 0 | 0 | link |
23.02.2022 | 25.02.2022 | DAMICO JENNIFER B. SVP & Controller |
Purchase | 27.34 | 321 190 | 11748 | 0 | 0 | link |
23.02.2022 | 25.02.2022 | DAMELIO FRANK A Executive Vice President |
Purchase | 27.34 | 4 204 590 | 153789 | 0 | 0 | link |
23.02.2022 | 25.02.2022 | Hwang Angela Group President |
Purchase | 27.34 | 583 955 | 21359 | 0 | 0 | link |
17.12.2021 | 21.12.2021 | BOURLA ALBERT Chairman & CEO |
Purchase | 26.73 | 3 289 260 | 123055 | 0 | 0 | link |
17.12.2021 | 21.12.2021 | Dolsten Mikael President R&D |
Purchase | 30.17 | 2 147 710 | 71187 | 0 | 0 | link |
11.11.2021 | 12.11.2021 | YOUNG JOHN D Group President |
Sale | 50.06 | 7 509 000 | 150000 | 0 | 0 | link |
30.07.2021 | 02.08.2021 | DAMICO JENNIFER B. SVP & Controller |
Sale | 42.86 | 107 150 | 2500 | 0 | 0 | link |
Institutions | Volume | Share, % |
---|---|---|
Vanguard Group Inc | 506517466 | 8.95 |
Blackrock Inc. | 432503754 | 7.64 |
State Street Corporation | 287482006 | 5.08 |
Wellington Management Group, LLP | 239209768 | 4.22 |
Capital World Investors | 173394272 | 3.06 |
Geode Capital Management, LLC | 109534217 | 1.93 |
Charles Schwab Investment Management, Inc. | 104246432 | 1.84 |
Morgan Stanley | 82106536 | 1.45 |
Norges Bank Investment Management | 73981480 | 1.31 |
Massachusetts Financial Services Co. | 68506441 | 1.21 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Ms. Jennifer B. Damico | Senior VP, Controller & Principal Accounting Officer | N/A | 1968 (56 years) |
Ms. Lidia L. Fonseca | Executive VP and Chief Digital & Technology Officer | N/A | 1969 (55 years) |
Mr. Douglas M. Lankler | Executive VP & General Counsel | 1.76M | 1966 (58 years) |
Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research & Development | 2.41M | 1958 (66 years) |
Mr. David M. Denton | Chief Financial Officer & Executive VP | 1.75M | 1965 (59 years) |
Mr. Rady A. Johnson | Executive VP and Chief Compliance, Quality & Risk Officer | N/A | 1962 (62 years) |
Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & CEO | 4.05M | 1962 (62 years) |
Ms. Francesca M. DeMartino | Chief Investor Relations Officer | N/A | |
Mr. Andreas J. Panayiotou | Global Chief Marketing Officer | N/A | |
Ms. Payal Sahni Becher | Chief People Experience Officer & Executive VP | 1975 (49 years) |
Website: http://www.pfizer.com